ID   ILVC_ECOLI              Reviewed;         491 AA.
AC   P05793; Q2M883;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   15-FEB-2017, entry version 156.
DE   RecName: Full=Ketol-acid reductoisomerase (NADP(+)) {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:2653423};
DE            Short=KARI {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:2653423};
DE            EC=1.1.1.86 {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000269|PubMed:15654896, ECO:0000269|PubMed:21515217, ECO:0000269|PubMed:2653423, ECO:0000269|PubMed:9015391};
DE   AltName: Full=Acetohydroxy-acid isomeroreductase {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:2653423};
DE            Short=AHIR {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:2653423};
DE   AltName: Full=Alpha-keto-beta-hydroxylacyl reductoisomerase {ECO:0000255|HAMAP-Rule:MF_00435};
DE   AltName: Full=Ketol-acid reductoisomerase type 2 {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:16322583};
DE   AltName: Full=Ketol-acid reductoisomerase type II {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000303|PubMed:16322583};
GN   Name=ilvC {ECO:0000255|HAMAP-Rule:MF_00435};
GN   OrderedLocusNames=b3774, JW3747;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INDUCTION.
RC   STRAIN=K12;
RX   PubMed=3003115;
RA   Wek R.C., Hatfield G.W.;
RT   "Nucleotide sequence and in vivo expression of the ilvY and ilvC genes
RT   in Escherichia coli K12. Transcription from divergent overlapping
RT   promoters.";
RL   J. Biol. Chem. 261:2441-2450(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=1379743; DOI=10.1126/science.1379743;
RA   Daniels D.L., Plunkett G. III, Burland V.D., Blattner F.R.;
RT   "Analysis of the Escherichia coli genome: DNA sequence of the region
RT   from 84.5 to 86.5 minutes.";
RL   Science 257:771-778(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-13.
RC   STRAIN=K12 / EMG2;
RX   PubMed=9298646; DOI=10.1002/elps.1150180807;
RA   Link A.J., Robison K., Church G.M.;
RT   "Comparing the predicted and observed properties of proteins encoded
RT   in the genome of Escherichia coli K-12.";
RL   Electrophoresis 18:1259-1313(1997).
RN   [6]
RP   INDUCTION.
RX   PubMed=3062177; DOI=10.1016/0022-2836(88)90199-4;
RA   Wek R.C., Hatfield G.W.;
RT   "Transcriptional activation at adjacent operators in the divergent-
RT   overlapping ilvY and ilvC promoters of Escherichia coli.";
RL   J. Mol. Biol. 203:643-663(1988).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR,
RP   SUBCELLULAR LOCATION, AND PATHWAY.
RX   PubMed=2653423; DOI=10.1021/bi00428a012;
RA   Chunduru S.K., Mrachko G.T., Calvo K.C.;
RT   "Mechanism of ketol acid reductoisomerase--steady-state analysis and
RT   metal ion requirement.";
RL   Biochemistry 28:486-493(1989).
RN   [8]
RP   ENZYME REGULATION.
RX   PubMed=2189496; DOI=10.1021/bi00463a027;
RA   Aulabaugh A., Schloss J.V.;
RT   "Oxalyl hydroxamates as reaction-intermediate analogues for ketol-acid
RT   reductoisomerase.";
RL   Biochemistry 29:2824-2830(1990).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF ARG-68; LYS-69; LYS-75 AND ARG-76.
RX   PubMed=9015391; DOI=10.1006/abbi.1996.9802;
RA   Rane M.J., Calvo K.C.;
RT   "Reversal of the nucleotide specificity of ketol acid reductoisomerase
RT   by site-directed mutagenesis identifies the NADPH binding site.";
RL   Arch. Biochem. Biophys. 338:83-89(1997).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR,
RP   MUTAGENESIS OF HIS-132; LYS-155; GLU-213; ASP-217; GLU-221; GLU-389;
RP   GLU-393 AND SER-414, AND SUBSTRATE SPECIFICITY.
RX   PubMed=15654896; DOI=10.1111/j.1742-4658.2004.04506.x;
RA   Tyagi R., Lee Y.T., Guddat L.W., Duggleby R.G.;
RT   "Probing the mechanism of the bifunctional enzyme ketol-acid
RT   reductoisomerase by site-directed mutagenesis of the active site.";
RL   FEBS J. 272:593-602(2005).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF ALA-71; ARG-76; SER-78 AND GLN-110.
RX   PubMed=21515217; DOI=10.1016/j.ymben.2011.02.004;
RA   Bastian S., Liu X., Meyerowitz J.T., Snow C.D., Chen M.M.,
RA   Arnold F.H.;
RT   "Engineered ketol-acid reductoisomerase and alcohol dehydrogenase
RT   enable anaerobic 2-methylpropan-1-ol production at theoretical yield
RT   in Escherichia coli.";
RL   Metab. Eng. 13:345-352(2011).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS), AND SUBUNIT.
RX   PubMed=16322583; DOI=10.1110/ps.051791305;
RA   Tyagi R., Duquerroy S., Navaza J., Guddat L.W., Duggleby R.G.;
RT   "The crystal structure of a bacterial class II ketol-acid
RT   reductoisomerase: domain conservation and evolution.";
RL   Protein Sci. 14:3089-3100(2005).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH MAGNESIUM AND
RP   NADP, COFACTOR, AND SUBUNIT.
RX   PubMed=23036858; DOI=10.1016/j.jmb.2012.09.018;
RA   Wong S.H., Lonhienne T.G., Winzor D.J., Schenk G., Guddat L.W.;
RT   "Bacterial and plant ketol-acid reductoisomerases have different
RT   mechanisms of induced fit during the catalytic cycle.";
RL   J. Mol. Biol. 424:168-179(2012).
CC   -!- FUNCTION: Involved in the biosynthesis of branched-chain amino
CC       acids (BCAA). Catalyzes an alkyl-migration followed by a ketol-
CC       acid reduction of (S)-2-acetolactate (S2AL) to yield (R)-2,3-
CC       dihydroxy-isovalerate. In the isomerase reaction, S2AL is
CC       rearranged via a Mg-dependent methyl migration to produce 3-
CC       hydroxy-3-methyl-2-ketobutyrate (HMKB). In the reductase reaction,
CC       this 2-ketoacid undergoes a metal-dependent reduction by NADPH to
CC       yield (R)-2,3-dihydroxy-isovalerate. Also able to use 2-
CC       ketopantoate, 2-ketoisovalerate, 2-ketovalerate, 2-ketobutyrate,
CC       3-hydroxypyruvate, 3-hydroxy-2-ketobutyrate and pyruvate
CC       (PubMed:15654896). {ECO:0000269|PubMed:15654896,
CC       ECO:0000269|PubMed:21515217, ECO:0000269|PubMed:2653423,
CC       ECO:0000269|PubMed:9015391}.
CC   -!- CATALYTIC ACTIVITY: (2R)-2,3-dihydroxy-3-methylbutanoate + NADP(+)
CC       = (2S)-2-hydroxy-2-methyl-3-oxobutanoate + NADPH.
CC       {ECO:0000255|HAMAP-Rule:MF_00435, ECO:0000269|PubMed:15654896,
CC       ECO:0000269|PubMed:21515217, ECO:0000269|PubMed:2653423,
CC       ECO:0000269|PubMed:9015391}.
CC   -!- CATALYTIC ACTIVITY: (2R,3R)-2,3-dihydroxy-3-methylpentanoate +
CC       NADP(+) = (S)-2-hydroxy-2-ethyl-3-oxobutanoate + NADPH.
CC       {ECO:0000255|HAMAP-Rule:MF_00435}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00435,
CC         ECO:0000269|PubMed:15654896, ECO:0000269|PubMed:23036858,
CC         ECO:0000269|PubMed:2653423};
CC       Note=Binds 2 magnesium ions per subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_00435, ECO:0000269|PubMed:23036858,
CC       ECO:0000269|PubMed:2653423};
CC   -!- ENZYME REGULATION: Inhibited by N-hydroxy-N-isopropyloxamate
CC       (IpOHA). {ECO:0000269|PubMed:2189496}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.04 mM for NADPH {ECO:0000269|PubMed:21515217};
CC         KM=0.042 mM for NADP {ECO:0000269|PubMed:9015391};
CC         KM=0.073 mM for NADPH {ECO:0000269|PubMed:9015391};
CC         KM=0.17 mM for 2-ketopantoate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         KM=0.206 mM for NADH {ECO:0000269|PubMed:9015391};
CC         KM=0.21 mM for 3-hydroxy-2-ketobutyrate (at pH 8 and 37 degrees
CC         Celsius) {ECO:0000269|PubMed:15654896};
CC         KM=0.25 mM for 2-acetolactate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         KM=0.27 mM for 3-hydroxy-3-methyl-2-ketobutyrate (at pH 8 and 37
CC         degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         KM=0.42 mM for magnesium (with S2AL and NADPH as substrates)
CC         {ECO:0000269|PubMed:2653423};
CC         KM=1.08 mM for NADH {ECO:0000269|PubMed:21515217};
CC         KM=1.54 mM for pyruvate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:2653423};
CC         KM=2.96 mM for 3-hydroxypyruvate (at pH 8 and 37 degrees
CC         Celsius) {ECO:0000269|PubMed:2653423};
CC         KM=3.15 mM for 2-ketovalerate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:2653423};
CC         KM=4.56 mM for 2-ketobutyrate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:2653423};
CC         KM=6.91 mM for 2-ketoisovalerate (at pH 8 and 37 degrees
CC         Celsius) {ECO:0000269|PubMed:2653423};
CC         Vmax=5.421 umol/min/mg enzyme with 3-hydroxypyruvate as
CC         substrate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         Vmax=3.541 umol/min/mg enzyme with 3-hydroxy-3-methyl-2-
CC         ketobutyrate as substrate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         Vmax=2.25 umol/min/mg enzyme with 2-acetolactate as substrate
CC         (at pH 8 and 37 degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         Vmax=0.599 umol/min/mg enzyme with 3-hydroxy-2-ketobutyrate as
CC         substrate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         Vmax=0.196 umol/min/mg enzyme with 2-ketopantoate as substrate
CC         (at pH 8 and 37 degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         Vmax=0.184 umol/min/mg enzyme with 2-ketoisovalerate as
CC         substrate (at pH 8 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:15654896};
CC         Vmax=0.168 umol/min/mg enzyme with 2-ketobutyrate as substrate
CC         (at pH 8 and 37 degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         Vmax=0.05 umol/min/mg enzyme with 2-ketovalerate as substrate
CC         (at pH 8 and 37 degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         Vmax=0.021 umol/min/mg enzyme with pyruvate as substrate (at pH
CC         8 and 37 degrees Celsius) {ECO:0000269|PubMed:15654896};
CC         Note=Kcat is 7.2 min(-1) for reductoisomerase activity with
CC         NADPH as substrate (PubMed:9015391). Kcat is 3.1 min(-1) for
CC         reductoisomerase activity with NADPH as substrate
CC         (PubMed:9015391). Kcat is 0.11 min(-1) for reductoisomerase
CC         activity with NADH as substrate (PubMed:9015391). Kcat is 5.376
CC         sec(-1) for reductoisomerase activity with 3-hydroxypyruvate as
CC         substrate (at pH 8 and 37 degrees Celsius) (PubMed:15654896).
CC         Kcat is 3.6 sec(-1) for reductoisomerase activity with NADPH as
CC         substrate (PubMed:21515217). Kcat is 3.511 sec(-1) for
CC         reductoisomerase activity with 3-hydroxy-3-methyl-2-ketobutyrate
CC         as substrate (at pH 8 and 37 degrees Celsius) (PubMed:15654896).
CC         Kcat is 2.231 sec(-1) for reductoisomerase activity with 2-
CC         acetolactate as substrate (at pH 8 and 37 degrees Celsius)
CC         (PubMed:15654896). Kcat is 0.594 sec(-1) for reductoisomerase
CC         activity with 3-hydroxy-2-ketobutyrate as substrate (at pH 8 and
CC         37 degrees Celsius) (PubMed:15654896). Kcat is 0.3 sec(-1) for
CC         reductoisomerase activity with NADH as substrate
CC         (PubMed:21515217). Kcat is 0.194 sec(-1) for reductoisomerase
CC         activity with 2-ketopantoate as substrate (at pH 8 and 37
CC         degrees Celsius) (PubMed:15654896). Kcat is 0.182 sec(-1) for
CC         reductoisomerase activity with 2-ketoisovalerate as substrate
CC         (at pH 8 and 37 degrees Celsius) (PubMed:15654896). Kcat is
CC         0.167 sec(-1) for reductoisomerase activity with 2-ketobutyrate
CC         as substrate (at pH 8 and 37 degrees Celsius) (PubMed:15654896).
CC         Kcat is 0.05 sec(-1) for reductoisomerase activity with 2-
CC         ketovalerate as substrate (at pH 8 and 37 degrees Celsius)
CC         (PubMed:15654896). Kcat is 0.021 sec(-1) for reductoisomerase
CC         activity with pyruvate as substrate (at pH 8 and 37 degrees
CC         Celsius) (PubMed:15654896). {ECO:0000269|PubMed:15654896,
CC         ECO:0000269|PubMed:21515217, ECO:0000269|PubMed:9015391};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-isoleucine biosynthesis; L-
CC       isoleucine from 2-oxobutanoate: step 2/4. {ECO:0000255|HAMAP-
CC       Rule:MF_00435, ECO:0000305|PubMed:2653423}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-valine biosynthesis; L-valine
CC       from pyruvate: step 2/4. {ECO:0000255|HAMAP-Rule:MF_00435,
CC       ECO:0000305|PubMed:2653423}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:16322583,
CC       ECO:0000269|PubMed:23036858}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:2653423}.
CC   -!- INDUCTION: In the presence of acetohydroxybutyrate and
CC       acetolactate and by the activator IlvY.
CC       {ECO:0000269|PubMed:3003115, ECO:0000269|PubMed:3062177}.
CC   -!- SIMILARITY: Belongs to the ketol-acid reductoisomerase family.
CC       {ECO:0000255|HAMAP-Rule:MF_00435}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11689; AAA24029.1; -; Genomic_DNA.
DR   EMBL; M87049; AAA67577.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC76779.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77523.1; -; Genomic_DNA.
DR   PIR; A65181; ISECKR.
DR   RefSeq; NP_418222.1; NC_000913.3.
DR   RefSeq; WP_000024939.1; NZ_LN832404.1.
DR   PDB; 1YRL; X-ray; 2.60 A; A/B/C/D=1-491.
DR   PDB; 3ULK; X-ray; 2.30 A; A/B=1-491.
DR   PDBsum; 1YRL; -.
DR   PDBsum; 3ULK; -.
DR   ProteinModelPortal; P05793; -.
DR   SMR; P05793; -.
DR   BioGrid; 4263331; 5.
DR   IntAct; P05793; 4.
DR   STRING; 511145.b3774; -.
DR   BindingDB; P05793; -.
DR   ChEMBL; CHEMBL2366462; -.
DR   SWISS-2DPAGE; P05793; -.
DR   EPD; P05793; -.
DR   PaxDb; P05793; -.
DR   PRIDE; P05793; -.
DR   EnsemblBacteria; AAC76779; AAC76779; b3774.
DR   EnsemblBacteria; BAE77523; BAE77523; BAE77523.
DR   GeneID; 948286; -.
DR   KEGG; ecj:JW3747; -.
DR   KEGG; eco:b3774; -.
DR   PATRIC; 32123043; VBIEscCol129921_3891.
DR   EchoBASE; EB0490; -.
DR   EcoGene; EG10495; ilvC.
DR   eggNOG; ENOG4105C6M; Bacteria.
DR   eggNOG; COG0059; LUCA.
DR   HOGENOM; HOG000286135; -.
DR   InParanoid; P05793; -.
DR   KO; K00053; -.
DR   OMA; KLFEMNR; -.
DR   PhylomeDB; P05793; -.
DR   BioCyc; EcoCyc:KETOLREDUCTOISOM-MONOMER; -.
DR   BioCyc; MetaCyc:KETOLREDUCTOISOM-MONOMER; -.
DR   BRENDA; 1.1.1.86; 2026.
DR   UniPathway; UPA00047; UER00056.
DR   UniPathway; UPA00049; UER00060.
DR   EvolutionaryTrace; P05793; -.
DR   PRO; PR:P05793; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005829; C:cytosol; IDA:EcoCyc.
DR   GO; GO:0004455; F:ketol-acid reductoisomerase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0050661; F:NADP binding; IDA:UniProtKB.
DR   GO; GO:0009097; P:isoleucine biosynthetic process; IDA:EcoCyc.
DR   GO; GO:0009099; P:valine biosynthetic process; IDA:EcoCyc.
DR   Gene3D; 1.10.1040.10; -; 1.
DR   Gene3D; 3.40.50.720; -; 1.
DR   HAMAP; MF_00435; IlvC; 1.
DR   InterPro; IPR008927; 6-PGluconate_DH_C-like.
DR   InterPro; IPR013328; 6PGD_dom_2.
DR   InterPro; IPR000506; AcH_isomrdctse_C.
DR   InterPro; IPR013116; IlvN.
DR   InterPro; IPR013023; Ketol-acid_reductoisomrdctse.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   PANTHER; PTHR21371; PTHR21371; 1.
DR   Pfam; PF01450; IlvC; 2.
DR   Pfam; PF07991; IlvN; 1.
DR   SUPFAM; SSF48179; SSF48179; 2.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00465; ilvC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amino-acid biosynthesis;
KW   Branched-chain amino acid biosynthesis; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Magnesium; Metal-binding; NADP;
KW   Nucleotide-binding; Oxidoreductase; Reference proteome; Repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:9298646}.
FT   CHAIN         2    491       Ketol-acid reductoisomerase (NADP(+)).
FT                                /FTId=PRO_0000151309.
FT   DOMAIN       35    204       IlvN. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000305|PubMed:16322583}.
FT   DOMAIN      210    342       IlvC 1. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000305|PubMed:16322583}.
FT   DOMAIN      357    482       IlvC 2. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000305|PubMed:16322583}.
FT   NP_BIND      45     48       NADP. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   NP_BIND     108    110       NADP. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   ACT_SITE    132    132       {ECO:0000255|HAMAP-Rule:MF_00435}.
FT   METAL       217    217       Magnesium 1. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   METAL       217    217       Magnesium 2. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   METAL       221    221       Magnesium 1. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435}.
FT   METAL       389    389       Magnesium 2. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   METAL       393    393       Magnesium 2. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   BINDING      68     68       NADP. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000305|PubMed:9015391}.
FT   BINDING      76     76       NADP. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858,
FT                                ECO:0000305|PubMed:9015391}.
FT   BINDING      78     78       NADP. {ECO:0000255|HAMAP-Rule:MF_00435,
FT                                ECO:0000269|PubMed:23036858}.
FT   BINDING     158    158       NADP; via amide nitrogen.
FT                                {ECO:0000255|HAMAP-Rule:MF_00435}.
FT   BINDING     414    414       Substrate. {ECO:0000255|HAMAP-
FT                                Rule:MF_00435}.
FT   MUTAGEN      68     68       R->D: Inversion of cofactor specificity
FT                                from NADPH to NADH; when associated with
FT                                L-69, V-75 and D-76.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      68     68       R->Q: 18-fold decrease of the catalytic
FT                                efficiency and 3-fold decrease of the
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      69     69       K->L: Does not significantly alter the
FT                                affinity for NADPH. Slight increase of
FT                                the catalytic efficiency. Inversion of
FT                                cofactor specificity from NADPH to NADH;
FT                                when associated with D-68, V-75 and D-76.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      71     71       A->S: 7- and 2.5-fold increase of the
FT                                reductoisomerase activity with NADH and
FT                                NADPH, respectively.
FT                                {ECO:0000269|PubMed:21515217}.
FT   MUTAGEN      75     75       K->Q: 13-fold decrease of the catalytic
FT                                efficiency and 3-fold increase of the
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      75     75       K->V: Inversion of cofactor specificity
FT                                from NADPH to NADH; when associated with
FT                                D-68, L-69 and D-76.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      76     76       R->D: 3-fold increase of the
FT                                reductoisomerase activity with NADH and
FT                                slight decrease of the reductoisomerase
FT                                activity with NADPH.
FT                                {ECO:0000269|PubMed:21515217}.
FT   MUTAGEN      76     76       R->D: Strong increase of catalytic
FT                                efficiency and 2.5-fold increase of the
FT                                affinity for NADH. 4-fold decrease of the
FT                                catalytic efficiency and strong decrease
FT                                of the affinity for NADPH. Inversion of
FT                                cofactor specificity from NADPH to NADH;
FT                                when associated with D-68, L-69 and V-75.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      76     76       R->Q: 20-fold decrease of the catalytic
FT                                efficiency and 5-fold decrease of the
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:9015391}.
FT   MUTAGEN      78     78       S->D: 12-fold increase of the
FT                                reductoisomerase activity with NADH and
FT                                slight decrease of the reductoisomerase
FT                                activity with NADPH.
FT                                {ECO:0000269|PubMed:21515217}.
FT   MUTAGEN     110    110       Q->V,A: 12- and 2-fold increase of the
FT                                reductoisomerase activity with NADH and
FT                                NADPH, respectively.
FT                                {ECO:0000269|PubMed:21515217}.
FT   MUTAGEN     132    132       H->K: Loss of reductoisomerase activity.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     132    132       H->Q: Loss of reductoisomerase activity.
FT                                The reductase activity with 3-
FT                                hydroxypyruvate and HMKB is nearly
FT                                normal, and the isomerase activity
FT                                decreases 24-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     155    155       K->E,Q: Loss of reductoisomerase
FT                                activity. {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     155    155       K->R: Loss of reductoisomerase activity.
FT                                The reductase activity with 3-
FT                                hydroxypyruvate and HMKB is nearly
FT                                normal, and the isomerase activity
FT                                decreases 40-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     213    213       E->D: Loss of reductoisomerase activity.
FT                                1.5-fold decrease of the reductase
FT                                activity with 3-hydroxypyruvate and the
FT                                isomerase activity decreases 48-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     217    217       D->E,N: Loss of reductoisomerase
FT                                activity. {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     221    221       E->D,Q: Loss of reductoisomerase
FT                                activity. {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     389    389       E->D: Loss of reductoisomerase activity.
FT                                1.5-fold decrease of the reductase
FT                                activity with 3-hydroxypyruvate and the
FT                                isomerase activity decreases 4-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     389    389       E->Q: Loss of reductoisomerase activity.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     393    393       E->D: Loss of reductoisomerase activity.
FT                                The reductase activity with HMKB is
FT                                nearly normal.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     414    414       S->A: Loss of reductoisomerase activity.
FT                                The isomerase activity decreases 15-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   MUTAGEN     414    414       S->T: Loss of reductoisomerase activity.
FT                                The isomerase activity decreases 24-fold.
FT                                {ECO:0000269|PubMed:15654896}.
FT   CONFLICT    251    251       E -> K (in Ref. 1; AAA24029).
FT                                {ECO:0000305}.
FT   HELIX         5      7       {ECO:0000244|PDB:3ULK}.
FT   HELIX        10     17       {ECO:0000244|PDB:3ULK}.
FT   STRAND       20     22       {ECO:0000244|PDB:1YRL}.
FT   HELIX        25     28       {ECO:0000244|PDB:3ULK}.
FT   TURN         29     32       {ECO:0000244|PDB:3ULK}.
FT   HELIX        33     35       {ECO:0000244|PDB:3ULK}.
FT   STRAND       38     44       {ECO:0000244|PDB:3ULK}.
FT   HELIX        47     58       {ECO:0000244|PDB:3ULK}.
FT   STRAND       62     67       {ECO:0000244|PDB:3ULK}.
FT   HELIX        69     73       {ECO:0000244|PDB:3ULK}.
FT   HELIX        77     84       {ECO:0000244|PDB:3ULK}.
FT   STRAND       88     91       {ECO:0000244|PDB:3ULK}.
FT   HELIX        92     95       {ECO:0000244|PDB:3ULK}.
FT   HELIX        96     98       {ECO:0000244|PDB:3ULK}.
FT   STRAND      100    104       {ECO:0000244|PDB:3ULK}.
FT   HELIX       108    110       {ECO:0000244|PDB:3ULK}.
FT   HELIX       111    118       {ECO:0000244|PDB:3ULK}.
FT   HELIX       119    121       {ECO:0000244|PDB:3ULK}.
FT   STRAND      127    132       {ECO:0000244|PDB:3ULK}.
FT   HELIX       134    137       {ECO:0000244|PDB:3ULK}.
FT   STRAND      147    156       {ECO:0000244|PDB:3ULK}.
FT   HELIX       158    166       {ECO:0000244|PDB:3ULK}.
FT   STRAND      173    177       {ECO:0000244|PDB:3ULK}.
FT   HELIX       179    181       {ECO:0000244|PDB:3ULK}.
FT   HELIX       187    197       {ECO:0000244|PDB:3ULK}.
FT   HELIX       200    202       {ECO:0000244|PDB:3ULK}.
FT   STRAND      205    207       {ECO:0000244|PDB:3ULK}.
FT   HELIX       210    222       {ECO:0000244|PDB:3ULK}.
FT   TURN        223    226       {ECO:0000244|PDB:3ULK}.
FT   HELIX       227    242       {ECO:0000244|PDB:3ULK}.
FT   HELIX       247    275       {ECO:0000244|PDB:3ULK}.
FT   HELIX       279    309       {ECO:0000244|PDB:3ULK}.
FT   HELIX       311    321       {ECO:0000244|PDB:3ULK}.
FT   TURN        322    324       {ECO:0000244|PDB:3ULK}.
FT   HELIX       325    336       {ECO:0000244|PDB:3ULK}.
FT   HELIX       338    341       {ECO:0000244|PDB:3ULK}.
FT   HELIX       351    356       {ECO:0000244|PDB:3ULK}.
FT   HELIX       359    377       {ECO:0000244|PDB:3ULK}.
FT   TURN        378    380       {ECO:0000244|PDB:3ULK}.
FT   HELIX       383    388       {ECO:0000244|PDB:3ULK}.
FT   HELIX       391    393       {ECO:0000244|PDB:3ULK}.
FT   HELIX       394    412       {ECO:0000244|PDB:3ULK}.
FT   HELIX       415    431       {ECO:0000244|PDB:3ULK}.
FT   HELIX       433    437       {ECO:0000244|PDB:3ULK}.
FT   STRAND      443    446       {ECO:0000244|PDB:3ULK}.
FT   HELIX       455    466       {ECO:0000244|PDB:3ULK}.
FT   HELIX       469    487       {ECO:0000244|PDB:3ULK}.
SQ   SEQUENCE   491 AA;  54069 MW;  9CA34BA61C9AEBBA CRC64;
     MANYFNTLNL RQQLAQLGKC RFMGRDEFAD GASYLQGKKV VIVGCGAQGL NQGLNMRDSG
     LDISYALRKE AIAEKRASWR KATENGFKVG TYEELIPQAD LVINLTPDKQ HSDVVRTVQP
     LMKDGAALGY SHGFNIVEVG EQIRKDITVV MVAPKCPGTE VREEYKRGFG VPTLIAVHPE
     NDPKGEGMAI AKAWAAATGG HRAGVLESSF VAEVKSDLMG EQTILCGMLQ AGSLLCFDKL
     VEEGTDPAYA EKLIQFGWET ITEALKQGGI TLMMDRLSNP AKLRAYALSE QLKEIMAPLF
     QKHMDDIISG EFSSGMMADW ANDDKKLLTW REETGKTAFE TAPQYEGKIG EQEYFDKGVL
     MIAMVKAGVE LAFETMVDSG IIEESAYYES LHELPLIANT IARKRLYEMN VVISDTAEYG
     NYLFSYACVP LLKPFMAELQ PGDLGKAIPE GAVDNGQLRD VNEAIRSHAI EQVGKKLRGY
     MTDMKRIAVA G
//
